For years, researchers who studied Ebola had tried to develop vaccines and drugs to combat the virus. And for years, they had seen promising work stimied by no potential for drug makers to recoup development costs; and the sporardic nature of Ebola outbreaks provided little opportunity to subject experimental vaccines to rigorous tests.
This is a database of novel vaccine candidates designed to provide broader and more durable protection against circulating and pandemic influenza viruses. The database includes investigational technologies that have reached clinical or late preclinical stages of development.
One Health is underutilized in the development of vaccines against shared human and animal disease threats.
This paper discusses scientific and policy issues related to vaccine platforms, and how they are understood in government, academia, and industry.
Although vaccines for the plague have been tried for decades, they have given only transient protection, and can’t protect against all forms of the plague, such as pneumonic plague.
Instead of using a single protein from the parasite, researchers are using entire parasites—which come with more than 5,000 proteins—deactivated with low doses of radiation.
The new technology allows researchers to quickly develop new vaccines, as well as tests able to distinguish between vaccinated animals and those infected.
The Uniformed Services University of the Health Sciences (USU), along with Profectus Biosciences, Inc., the Vanderbilt University Medical Center, Mapp Biopharmaceutical, Inc., and the University of Texas Medical Branch (UTMB), have been awarded up to $24.5 million to advance treatments for the highly lethal henipaviruses, Nipah and Hendra.
A concise network model developed by Washington State University researchers could help advance the understanding of disease-causing bacteria and guide vaccine development, such as for anaplasmosis in cattle.
In a move to defeat the next pandemic, the CEPI (Coalition for Epidemic Preparedness Innovations) has reportedly signed an agreement with CureVac, a German biopharmaceutical firm. The duo plan to develop a vaccine printing technology, with an aim to produce shots against various diseases.